The Role of Biomarkers in Acute Kidney Injury

Nattachai Srisawat; John A Kellum

doi:10.1016/j.ccc.2019.08.010

The Role of Biomarkers in Acute Kidney Injury

Crit Care Clin. 2020 Jan;36(1):125-140. doi: 10.1016/j.ccc.2019.08.010.

Authors

Nattachai Srisawat¹, John A Kellum²

Affiliations

¹ Division of Nephrology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand 3rd floor, Anantamahidol Building, Henri Dunant Road, Pathumwan, Bangkok 10330, Thailand; Department of Critical Care Medicine, Center for Critical Care Nephrology, The CRISMA Center, University of Pittsburgh School of Medicine, 3347 Forbes Avenue, Suite 220, Pittsburgh, PA 15213, USA; Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital, 1873 Rama IV Road, Khwaeng Pathum Wan, Khet Pathum Wan, Krung Thep Maha Nakhon 10330, Thailand; Critical Care Nephrology Research Unit, Chulalongkorn University, 3rd floor, Anantamahidol Building, Henri Dunant Road, Pathumwan, Bangkok 10330, Thailand; Academic of Science, Royal Society of Thailand, 197 Rama 5 Road Khwaeng Dusit, Khet Dusit, Bangkok 10300, Thailand; Tropical Medicine Cluster, Chulalongkorn University, 3rd floor, Anantamahidol Building, Henri Dunant Road, Pathumwan, Bangkok 10330, Thailand.
² Department of Critical Care Medicine, Center for Critical Care Nephrology, The CRISMA Center, University of Pittsburgh School of Medicine, 3347 Forbes Avenue, Suite 220, Pittsburgh, PA 15213, USA. Electronic address: kellum@pitt.edu.

PMID: 31733675
DOI: 10.1016/j.ccc.2019.08.010

Abstract

Several biomarkers have been developed to detect acute kidney injury (AKI) and predict outcomes. Most AKI biomarkers have been shown to be expressed before serum creatinine and to be more sensitive and specific than urine output. Only a few studies have examined how implementation can change clinical outcomes. A second generation of AKI biomarkers have been developed. These markers, including tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulinlike growth factor-binding protein 7 (IGFBP7), have obtained regulatory approval in many countries based on large, rigorous clinical studies and small, single-centered trials and have begun to establish clinical utility.

Keywords: IGFBP7; IL-18; KIM-1; NGAL; TIMP-2.

Publication types

Review

MeSH terms

Acute Kidney Injury / blood*
Acute Kidney Injury / diagnosis*
Biomarkers / blood*
Female
Humans
Insulin-Like Growth Factor Binding Proteins / blood*
Male
Matrix Metalloproteinase Inhibitors / blood*
Predictive Value of Tests

Substances

Biomarkers
Insulin-Like Growth Factor Binding Proteins
Matrix Metalloproteinase Inhibitors
insulin-like growth factor binding protein-related protein 1